Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management
Explore this paper's citation graph
Summary
Current available therapeutic agents, including supportive care, erythropoiesis-stimulating agents (ESAs), immune-modulating agents, hypomethylating agents, and HSCT are described in detail and discussed with a special focus on elderly MDS patients.
- Type
- article
- Published
- 2015-10-17
- Cited by
- 16
- References
- 130
- OpenAlex
- https://openalex.org/W1946193527
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:41844832
Keywords
Medicine, Myelodysplastic syndromes, Quality of life (healthcare), Intensive care medicine, Clinical trial
References
- A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life
- Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group.
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes
- A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
- Causes of initial remission induction failure in acute myelogenous leukemia.
- International scoring system for evaluating prognosis in myelodysplastic syndromes.
- Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation.
- Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomize
- Lenalidomide in lower‐risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis‐stimulating agents
- Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia
- Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme
- A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.
- “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician
- Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience.
- TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
- Prognostic impact of severe thrombocytopenia in low‐risk myelodysplastic syndrome
- Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis
- Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
- The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons
Cited by
- Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114 and 130 fL as critical markers for categorization
- Never too old to treat cancer?
- Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.
- Molecular features of early onset adult myelodysplastic syndrome
- Analysis of cytopenia in geriatric inpatients
- Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform
- Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study
- ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma
- Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
- Blood transfusion in older patients.
- Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age
- A flow cytometric approach to compare stem cell apoptosis in aplastic anemia and hypoplastic myelodysplastic syndrome.
- Clinical efficacy of azacitidine in the treatment of middle- and high-risk myelodysplastic syndrome in middle-aged and elderly patients: A retrospective study
- This is a repository copy of Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet
- Hematology and hemostasis in the pediatric, geriatric, and pregnant populations
- OP-ANNO170434 544..562
- Epigenetics in Myelodysplastic Syndromes
Related papers
- Erythroleukemia and myelodysplastic syndromes: an historical appraisal and a personal view.
- Infections in myelodysplastic syndromes
- Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes
- New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
- C014 Influence of different treatment strategies on the prognosis of patients with myelodysplastic syndromes (MDS)
- Épidémiologie des syndromes myélodysplasiques (SMD) et des syndromes myélodysplasiques/syndromes myéloprolifératifs (SMD/SMP)
- P129 Severe iron overload in patients with myelodysplastic syndromes (MDS) enrolled in a large study of deferasirox (Exjade®, ICL670)
- Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes
- Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myélodysplasies